Many organic small molecules serve as drug leads for drug discovery and drug development programs. Understanding the structure and mechanism of action of these small molecules is essential for drug lead optimization. Also having a reliable synthetic access to these organic small molecules is important to aid in SAR studies and lead optimization in the search for new drugs for various diseases. Dr. Adu-Ampratwum area of interest includes exploring novel synthetic methods for the synthesis of small organic molecules as lead compounds for drug discovery. His current research area focuses on designing and synthesizing small molecules to study HIV and cancer biology and as potential therapeutics.
- 2016 – 2021 - Postdoctoral Researcher in Medicinal Chemistry – The Ohio State University, Columbus OH
- 2010 – 2016 - PhD in Chemistry – The Ohio State University, Columbus OH
- 2008 – 2010 – MS in Chemistry – Indiana University of Pennsylvania, Indiana
- 2002-2006 - BS in Chemistry – Kwame Nkrumah University of Science & Technology, Kumasi, Ghana
- Tomatidine targets ATF4-dependent signaling and induces ferroptosis to limit pancreatic cancer progression, iScience. 2023 Aug | journal-article. doi: 10.1016/j.isci.2023.107408.
- Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir, mBio. 2022 Oct | journal-article. doi: 10.1128/mbio.01804-22.
- Identification and Optimization of a Novel HIV-1 Integrase Inhibitor, ACS Omega. 2022 Feb | journal-article. doi: 10.1021/acsomega.1c06378.
- Structural and mechanistic bases for a potent HIV-1 capsid inhibitor, Science. 2020 Oct | journal-article. doi: 10.1126/science.abb4808.
- HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors, eLife. 2019 May | journal-article. doi: 10.7554/eLife.46344.
- See more publications